Drug Trial Radar · NCT00999609
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
Last checked: Nov 20, 2026Latest source record: Apr 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
31
Actual
Start
Oct 2012
Primary completion
Jul 2015
Study completion Jan 2030
Sponsor
- Lead sponsor
- Spark Therapeutics, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Children's Hospital of Philadelphia; University of Iowa
- First posted
- Oct 22, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2 (voretigene neparvovec-rzyl). At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with RPE65 gene mutations.
Conditions
- Inherited Retinal Dystrophy Due to RPE65 Mutations
- Leber Congenital Amaurosis
Interventions
AAV2-hRPE65v2,voretigene neparvovec-rzylBiological
Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Multi-luminance Mobility Testing (MLMT), BilateralTime frame: One year (change from baseline)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University of Iowa
Iowa City, Iowa
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.